Caveat: subjective reports are extremely scarce, the molecule has been on the gray market for under three years, vendor purity is highly variable, and there is no PK basis for any community dose. What follows is a summary of the small public anecdotal pool with heavy caveats.

• First doses: Most reports describe a subtle but detectable rise in perceived warmth within hours to a day of starting. Not a "stim feel" — more like "the room is warmer than it should be" or "I'm sweating during normal activity." Resting heart rate may tick up 5-15 bpm.
• Week 1-2: Adaptation period. Most users report habituation to the warmth signal but a persistent low-grade thermogenic effect. Some report mild fatigue or reduced workout output — consistent with reduced ATP yield per substrate, especially in glycolytic / high-power efforts. Cardio at fixed pace may feel hotter than usual.
• Week 2-6: Subjective fat loss in users running a caloric deficit; modest in users at maintenance. Mechanism predicts the body burns more substrate per unit of work, so a user at maintenance intake should see a modest deficit emerge passively. Sleep may be disrupted, especially with later-day doses.
• Cycle off: Effects fade over days to a few weeks. No reports of withdrawal or rebound. Body composition changes appear to partially reverse if intake returns to surplus.
• Concerning patterns: Reports exist of users discontinuing due to palpitations, marked heat intolerance, or unexplained fatigue. These are the same patterns that historically preceded DNP fatalities — though none of the BAM-15 anecdotal pool has reported a fatality, the sample size is too small to draw confidence from.

Honesty about variability and signal interpretation: BAM-15 is not a stim. The headline subjective effect is feeling warmer than usual. Anyone who reports a strong "stim feel" is almost certainly running an impure batch, a stimulant-contaminated batch, or experiencing placebo. Reports of dramatic week-1 fat loss are almost certainly water shifts (uncouplers can affect fluid balance) or attribution noise from concurrent caloric restriction.

• Tolerance buildup: Unknown. Theoretical possibility that compensatory mitochondrial biogenesis offsets uncoupling over time (the body literally builds more mitochondria to compensate for the leak). Some rodent data suggests mild adaptive responses; no human data.
• Recommended cycle (if used at all): 4-6 weeks on, 8-12 weeks off. ≤2 cycles per year given thermogenic load and unknown chronic profile.
• Reset protocol: No specific reset needed. Half-life in rodents is on the order of hours; subjective effects fade over days to weeks post-cessation.
• Long-term cumulative use (years): Strongly cautioned against until human Phase 1 + chronic rodent oncology / cardiac / hepatic data exists. The DNP precedent is a long-term-safety cautionary tale even when acute dosing is sub-fatal.

Synergistic with

• None recommended. No stack synergy is currently mechanistically justified for BAM-15 in humans. The compound itself has no human safety data; building stacks on top of it compounds uncertainty.

Avoid stacking with

• DNP — additive uncoupling, additive lethal hyperthermia risk. Hard avoid.
• Cardarine (GW-501516) — both push fat oxidation hard; theoretical additive hepatic and metabolic load; Cardarine has its own carcinogenicity concerns. Hard avoid.
• SLU-PP-332 — both target the mitochondrial substrate-oxidation axis from different angles; no human safety data on either; functional opposition (SLU-PP-332 builds mitochondrial capacity, BAM-15 wastes its output as heat).
• MOTS-c — same logic as SLU-PP-332; mitochondrial-pathway-pushing compounds should not be stacked with an uncoupler.
• Semaglutide / tirzepatide / retatrutide — these are the FDA-approved, evidence-based answer to the same goal. No basis to add an unvalidated uncoupler to a working GLP-1 protocol.
• Stimulants (caffeine high-dose, modafinil, ephedrine, clenbuterol, yohimbine) — stimulants raise metabolic rate and core temp on their own; layering on an uncoupler reproduces the DNP fatality envelope.
• Thyroid hormone (T3/T4) — additive thermogenic and cardiac load; do not combine.
• Pre-workout supplements with high stimulant content — same logic; mechanistic risk amplification.

Neutral / safe co-administration

• All V4 daily core supplements (DHA, magnesium, citicoline, NAC, PS, curcumin, rhodiola, theanine, glycine/L-tryptophan, D3/K2, beta-alanine, vitamin C) — no documented mechanistic conflict, but adding noise to attribution during an experimental cycle.
• BPC-157, TB-500 — different mechanism (tissue repair), no documented overlap.

• CYP enzymes: BAM-15 metabolic profile in humans is uncharacterized. Conservative assumption: avoid combining with strong CYP inducers/inhibitors during a cycle.
• Hormonal contraceptives: No documented interaction (not relevant for the user). Theoretical: hepatic metabolism shifts could affect contraceptive metabolism.
• Anticoagulants: No documented interaction.
• Alcohol: Acutely impairs hepatic mitochondrial function; combined with BAM-15 (which is increasing hepatic substrate flux and mild thermogenic load) is poor pairing. The user is alcohol-free, so non-issue in practice.
• Caffeine: Mechanistic concern — both raise metabolic rate; theoretical additive thermogenic and cardiac load. The user is on a low-caffeine baseline; do not introduce a higher caffeine load during any cycle.
• Stimulant medications (Adderall, modafinil): Avoid. Mechanism stack reproduces the DNP fatality envelope.
• Statins: Statins can affect mitochondrial function in muscle. Combining with an uncoupler is mechanistically opposing; clinical effect unknown. Not relevant for the user.
• Other peptides (BPC-157, TB-500): No documented interactions; mechanism layers non-overlapping.

• No BAM-15-specific pharmacogenomic data exists. The molecule has not been administered to humans in any genotyped cohort.
• Indirect candidate gene relevance (theoretical):
  • UCP1, UCP2, UCP3 variants — endogenous uncoupling protein variants modulate basal thermogenic capacity. Theoretical modulators of BAM-15 response and heat-stress tolerance. No clinical data.
  • CYP enzyme variants — relevant if metabolic clearance pathway becomes characterized.
  • PPARGC1A (PGC-1α) Gly482Ser (rs8192678) — affects mitochondrial biogenesis response. Theoretical modulator of compensatory adaptation to chronic uncoupling.

Action item if the user ever overrides verdict (not recommended): Pull UCP1/UCP2/UCP3 status from 23andMe (results June 2026) — speculative but the only available genomic data point.

Cost math (if the user overrides verdict — not recommended):

• One 4-week cycle at 25 mg/day = 700 mg total. At 1g vendor pricing ($50-120), one cycle costs ~$35-85 in raw material — cheap. Cost is not a barrier.
• The real cost is the safety-uncertainty premium and the bloodwork (CBC, CMP, lipid, fasting insulin, ALT/AST, TSH/T3/T4 pre/post = ~$150-350 if not covered).
• Cost is not the reason to avoid this compound. The reason is the absent human safety data + lethal mechanism class precedent + no plausible benefit profile for this user.

Quality verification on receipt:

• COA: ≥98% purity by HPLC, ideally with mass spec confirmation, lot number traceable
• For powder form: appearance should be pale yellow to off-white crystalline solid; bright yellow or orange suggests DNP contamination — discard
• Reconstitution / dissolution test (if liquid product): solution should be clear; cloudiness or particulates → discard
• Third-party independent test (recommended for any user who overrides verdict): Janoshik Analytical or similar offers independent research-chem testing. For an uncoupler, paying $40-80 for independent analysis on a representative lot is appropriate due diligence — purity matters more here than for most research chems because of the structural similarity to DNP.

Baseline (before any cycle, if user overrides verdict — not recommended)

• CBC, CMP, lipid panel, hsCRP, fasting glucose, fasting insulin, HOMA-IR, HbA1c — full V4-baseline bloodwork (already planned for June 2026)
• ALT, AST, GGT, alkaline phosphatase — hepatic markers; BAM-15 has hepatic exposure and substrate-flux load on the liver
• TSH, free T3, free T4 — thyroid function; baseline before adding any thermogenic agent
• Body composition (DEXA preferred) — fat %, lean mass, visceral fat
• Resting heart rate, HRV (Whoop / Oura) — autonomic baseline; key safety signal during cycle
• Resting AM oral temperature — hourly logging in week 1, daily thereafter; key safety signal
• Resting blood pressure
• ECG (12-lead) baseline — particularly important given mechanism class cardiac risk
• Urinary catecholamines (research-tier; if accessible) — adrenergic load baseline
• Subjective baseline log: sleep quality, RPE during training, recovery, appetite, perceived warmth at rest

During cycle

• Daily AM oral temperature for the first 7 days, then 3×/week
• Daily resting HR (first thing in the morning) for the first 14 days
• Adverse event log — palpitations, sweating disproportionate to environment, fatigue, sleep disruption, headache, GI symptoms
• Mid-cycle bloodwork (day 14): ALT, AST, CMP, fasting glucose, lipid panel
• Body composition mid-cycle (week 3-4)

Post-cycle (2 weeks after stop)

• Repeat full bloodwork: CBC, CMP (especially ALT, AST), fasting glucose, fasting insulin, HOMA-IR, lipid panel, hsCRP, TSH/T3/T4
• Repeat body composition (DEXA)
• Repeat ECG (cardiac safety reassurance)
• Subjective recap: clear signal vs nothing? worth continuing? any abnormal lab → discontinue permanently and do not re-cycle

Decision rule: if pre/post bloodwork shows any abnormality (especially hepatic, thyroid, or cardiac), discontinue permanently. If resting temperature climbed >37.8°C at any point during cycle, discontinue immediately and do not re-cycle. Default expectation for a 20yo lean athlete: there will be no positive signal worth the risk profile, and the rational decision will be to drop the compound until a human Phase 1 reads out.